logo-loader
viewAvalon GloboCare Corp

Avalon GloboCare to repurchase all outstanding warrants for about $1.4M

The warrants, totaling about 1.7 million, were originally issued to 3rd-party institutional investors in connection with a registered direct offering on April 25, 2019

Avalon GloboCare Corp - Avalon GloboCare Corp of New Jersey to repurchase all of the company’s outstanding warrants for about $1.4 million
Avalon GloboCare, based in Freehold, New Jersey, is a clinical-stage, leading CellTech bio-developer

Avalon GloboCare Corp (NASDAQ:AVCO) announced Monday its plans to repurchase all of the company’s outstanding warrants for about $1.4 million. 

The warrants, totaling about 1.7 million, were originally issued to third-party institutional investors in connection with a registered direct offering on April 25, 2019. The transaction is expected to close on or before November 8, at which time the repurchased warrants will be retired and canceled.

“We believe the repurchase of these warrants, combined with the recently announced $20 million non-convertible line of credit from our chairman, provides a platform for significant growth with less potential dilution,” said CEO Dr  David Jin in a statement.  

READ: Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma

“This repurchase enhances our capital structure and demonstrates the confidence that we have in the future of the company. We are advancing towards the next phase of growth as an active clinical-stage company.”

Jin added: “We have a strong pipeline of cellular immunotherapy candidates and we look forward to continuing to advance our clinical studies using our cellular therapeutic platforms in CAR-T and stem cell derived exosomes. We believe that our strong balance sheet leaves us well-positioned to take advantage of future opportunities to create value for our shareholders.”

Avalon GloboCare, based in Freehold, New Jersey, is a clinical-stage, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Avalon GloboCare Corp

Price: 1.47 USD

NASDAQ:AVCO
Market: NASDAQ
Market Cap: $112.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Avalon GloboCare reaches 'major clinical milestone' by...

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive the New Jersey-based company has reached a 'major clinical milestone' by beginning the first-in-human Phase I clinical trial of its flagship AVA-001 therapy in China to treat relapsed/refractory B-cell malignancies, including...

on 10/04/2019

2 min read